(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 May 2014 (30.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/081954 A1

(51) **International Patent Classification**:
C07K 16/00 (2006.01)

(21) **International Application Number**:
PCT/US2013/071288

(22) **International Filing Date**:
21 November 2013 (21.11.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/728,912	21 November 2012 (21.11.2012)	US
61/782,550	14 March 2013 (14.03.2013)	US
61/809,541	8 April 2013 (08.04.2013)	US
61/864,717	12 August 2013 (12.08.2013)	US
61/892,797	18 October 2013 (18.10.2013)	US

(71) **Applicant**: **JANSSEN BIOTECH, INC.** [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US).

(72) **Inventors**: **CHIU, Mark**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **MOORES, Sheri**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **NEIJSSEN, Joost**; Yalelaan 60, NL-3854 Ultrecht (NL). **PARREN, Paul**; Yalelaan 60, NL-3854 Ultrecht (NL). **SCHUURMAN, Janine**; Yalelaan 60, NL-3854 Ultrecht (NL).

(74) **Agents**: **JOHNSON, Philip, S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

[Continued on next page]

(54) **Title**: BISPECIFIC EGFR/c-Met ANTIBODIES

Figure 1A.



SEQ ID NO:		
18	LPAPKNLVVSEVTEDSLRLSWADP-HGFYDSFLIQYQESEKVGEAINLTVPGSERSYDLTG	(60)
19	LPAPKNLVVSEVTEDSLRLSWTYD-RDGYDSFLIQYQESEKVGEAINLTVPGSERSYDLTG	
20	LPAPKNLVVSEVTEDSLRLSWGYN-GDHFDSFLIQYQESEKVGEAINLTVPGSERSYDLTG	
21	LPAPKNLVVSEVTEDSLRLSWDDP-RGFYESFLIQYQESEKVGEAINLTVPGSERSYDLTG	
22	LPAPKNLVVSEVTEDSLRLSWTWP-YADLDSFLIQYQESEKVGEAINLTVPGSERSYDLTG	
23	LPAPKNLVVSEVTEDSLRLSWGYN-GDHFDSFLIQYQESEKVGEAINLTVPGSERSYDLTG	
24	LPAPKNLVVSEVTEDSLRLSWDYDLGDHFDSFLIQYQESEKVGEAINLTVPGSERSYDLTG	
25	LPAPKNLVVSEVTEDSLRLSWDDP-WAFYESFLIQYQESEKVGEAINLTVPGSERSYDLTG	
27	LPAPKNLVVSEVTEDSARLSWDDP-WAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG	
29	LPAPKNLVVSEVTEDSLRLSWTWP-YADLDSFLIQYQESEKVGEAINLTVPGSERSYDLTG	
107	LPAPKNLVVSEVTEDSARLSWADP-HGFYDSFLIQYQESEKVGEAIVLTVPGSERSYDLTG	
108	LPAPKNLVVSEVTEDSARLSWDDP-WAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG	
109	LPAPKNLVVSEVTEDSARLSWDDP-HAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG	
110	LPAPKNLVVSEVTEDSARLSWADP-HGFYDSFLIQYQESEKVGEAIVLTVPGSERSYDLTG	
	********** **** :********** **********	
18	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	(94)
19	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
20	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
21	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
22	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
23	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
24	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
25	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
27	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAIFTT	
29	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT	
107	LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAIFTT	
108	LKPGTEYTVSIYGVHNVYKDTNIRGLPLSAIFTT	
109	LKPGTEYTVSIYGVHNVYKDTNIRGLPLSAIFTT	
110	LKPGTEYTVSIYGVHNVYKDTNIRGLPLSAIFTT	

(57) **Abstract**: Bispecific EGFR/c-Met antibodies and methods making and using the molecules. Epidermal growth factor receptor (EGFR, ErbBI or HERI) is a Type I transmembmne glycoprotein of 170 kDa thai is encoded by the c-erbBI proto-oncogene. EGFR is a member of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases (RTK) which includes HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). EGFR signaling is initiated by ligand binding followed by induction of conformational change, homodimerizalion or heteromdimerization of the receptor with other ErbB family members.

WO 2014/081954 A1

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*